The massive dilution to ~10.4% for existing holders is a certain present event, while the $4B valuation and business plan are contingent and unverified. Monitor for definitive agreements, fairness opinion outcome, and liability reduction progress. The reverse split and ATM filing signal near-term capital needs. The stock may trade on deal speculation but faces structural dilution risk.
Price Chart
Executive Summary
Wellgistics Health entered a fully binding term sheet to acquire QOLPOM drone/biometric IP from EOS and SCLX, expand its PharmacyChain license with Datavault AI, and acquire a controlling stake in Tollo Health, forming DelivMeds AI with an expected combined asset value of $4B. Concurrently, the company upsized a convertible note by $250K (to $1.5M principal), appointed Gerald Commissiong as Interim Co-CEO, and filed a 1-for-50 reverse stock split to regain Nasdaq compliance. Existing public shareholders are diluted to ~10.4% post-conversion of Acquisition Preferred, while the transaction remains subject to due diligence, fairness opinion, financing, and definitive agreements.
Key Financial Metrics
Key Facts
- Entered fully binding term sheet to form DelivMeds AI via acquisition of QOLPOM IP from EOS/SCLX, PharmacyChain license expansion with DVLT, and controlling stake in Tollo Health.
- Expected combined asset value of $4B, subject to independent fairness opinion.
- Upon conversion of Acquisition Preferred, EOS, SCLX, DVLT, Fortitude, and HBA will own ~89.6% of WGRX common; existing public shareholders retain ~10.4%.
- Target concurrent minimum $2M investment from Dawson James investors; ATM facility to be filed within 14 days.
- Amended note purchase agreement with Robert Forster: additional $200K cash funded, note principal increased to $1.5M (20% OID).
- Gerald Commissiong appointed Interim Co-CEO; Dan Hirsch hired as interim-VP of Finance.
- 1-for-50 reverse stock split effective May 26, 2026 to regain Nasdaq minimum bid price compliance.
- Transaction contingent on due diligence, fairness opinion, board approvals, shareholder vote/consent, financing, and Nasdaq listing maintenance.
Financial Impact
Existing public shareholders diluted to ~10.4% post-conversion; $4B expected combined asset value; $2M immediate capital target; $5M minimum operating capital at close; $20M minimum cash investment at conversion.
Risk Factors
- Massive dilution: existing shareholders reduced to ~10.4% post-conversion of Acquisition Preferred.
- Transaction may not close: subject to due diligence, fairness opinion, financing, and approvals.
- $4B valuation is aspirational and unsupported by current financials; fairness opinion may not support it.
- Reverse stock split does not guarantee Nasdaq compliance; delisting risk remains.
- Company has significant outstanding liabilities to be settled; failure could scuttle the deal.
- ATM filing and additional financings could further dilute existing holders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-024723 |
| Exhibit: ex10-2.htm | 0001493152-26-024723 |
| Exhibit: ex99-2.htm | 0001493152-26-024723 |
| Exhibit: ex10-3.htm | 0001493152-26-024723 |
| Exhibit: ex99-1.htm | 0001493152-26-024723 |
| Exhibit: ex3-1.htm | 0001493152-26-024723 |
| Document: form8-k.htm | 0001493152-26-024723 |
| Document: 0001493152-26-024723-index-headers.html | 0001493152-26-024723 |
| Document: 0001493152-26-024723-index.html | 0001493152-26-024723 |
| Document: 0001493152-26-024723.txt | 0001493152-26-024723 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | S-1/A | — | awaiting T+20 | — | — |
May 29, 2026 21w ago | 8-K | $3.85 $3.10 | ▲ +19.48% | ▲ +18.18% | — |
May 21, 2026 22w ago | 8-K | $5.35 $3.18 | ▼ −40.52% | ▼ −40.85% | — |
May 19, 2026 22w ago | 8-K | $6.45 $3.39 | ▼ −47.44% | ▼ −48.18% | — |
May 19, 2026 22w ago | 8-K | $8.40 $3.70 | ▼ −55.95% | ▼ −56.94% | — |
May 18, 2026 23w ago | 8-K | $8.70 $3.69 | ▼ −57.59% | ▼ −59.17% | — |
May 8, 2026 24w ago | EFFECT | $4.21 $4.35 | ▼ −3.33% | ▼ −3.30% | — |
Apr 24, 2026 26w ago | 10-K/A | $6.23 $3.82 | ▲ +38.68% | ▲ +43.64% | — |
Apr 17, 2026 27w ago | 8-K | $6.60 $8.70 | ▲ +31.82% | ▲ +27.62% | — |
Apr 15, 2026 27w ago | S-3 | $7.37 $4.70 | ▼ −36.18% | ▼ −42.82% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers